BR112022005024A2 - Anti-nrp1a antibodies and their uses for the treatment of eyes or eye diseases - Google Patents
Anti-nrp1a antibodies and their uses for the treatment of eyes or eye diseasesInfo
- Publication number
- BR112022005024A2 BR112022005024A2 BR112022005024A BR112022005024A BR112022005024A2 BR 112022005024 A2 BR112022005024 A2 BR 112022005024A2 BR 112022005024 A BR112022005024 A BR 112022005024A BR 112022005024 A BR112022005024 A BR 112022005024A BR 112022005024 A2 BR112022005024 A2 BR 112022005024A2
- Authority
- BR
- Brazil
- Prior art keywords
- nrp1a
- antibodies
- eyes
- treatment
- eye diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
anticorpos anti-nrp1a e seus usos para o tratamento dos olhos ou doenças oculares. a presente invenção refere-se a anticorpos e fragmentos dos mesmos que se direcionam ao domínio a de neuropilina-1 (nrp1a). mais especificamente, os anticorpos anti-nrp1a e os métodos de uso para o trata-mento de várias doenças ou distúrbios são descritos.anti-nrp1a antibodies and their uses for treating eyes or eye diseases. the present invention relates to antibodies and fragments thereof that target the a domain of neuropilin-1 (nrp1a). more specifically, anti-nrp1a antibodies and methods of use for treating various diseases or disorders are described.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19199099 | 2019-09-24 | ||
EP20150942 | 2020-01-09 | ||
PCT/EP2020/076685 WO2021058636A1 (en) | 2019-09-24 | 2020-09-24 | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022005024A2 true BR112022005024A2 (en) | 2022-06-21 |
Family
ID=72752879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022005024A BR112022005024A2 (en) | 2019-09-24 | 2020-09-24 | Anti-nrp1a antibodies and their uses for the treatment of eyes or eye diseases |
Country Status (16)
Country | Link |
---|---|
US (2) | US11661458B2 (en) |
EP (1) | EP4034161A1 (en) |
JP (1) | JP2022549005A (en) |
KR (1) | KR20220069076A (en) |
CN (1) | CN114423788A (en) |
AU (1) | AU2020355599A1 (en) |
BR (1) | BR112022005024A2 (en) |
CA (1) | CA3154654A1 (en) |
CO (1) | CO2022003324A2 (en) |
CR (1) | CR20220122A (en) |
IL (1) | IL291522A (en) |
JO (1) | JOP20220074A1 (en) |
MX (1) | MX2022003544A (en) |
PE (1) | PE20221315A1 (en) |
TW (1) | TW202126685A (en) |
WO (1) | WO2021058636A1 (en) |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (en) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | blood substitute |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (en) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Process for the biotechnical production of alkaline phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
ATE135397T1 (en) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS |
FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
UA96139C2 (en) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
AU2011253904B2 (en) | 2005-11-08 | 2014-02-13 | Genentech, Inc. | Neuropilin antagonists |
EP2158215B1 (en) | 2007-05-17 | 2015-04-22 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
WO2014127479A1 (en) | 2013-02-21 | 2014-08-28 | Rsem, Limited Partnership | Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability |
ES2865488T3 (en) | 2014-09-05 | 2021-10-15 | Rsem Lp | Compositions and methods for the treatment and prevention of inflammation |
JP6475835B2 (en) | 2014-12-03 | 2019-02-27 | サムスン ライフ パブリック ウェルフェア ファウンデーションSamsung Life Public Welfare Foundation | Antibody against neuropilin 1 and use thereof |
JOP20190134A1 (en) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | Anti-neuropilin antigen-binding proteins and methods of use thereof |
-
2020
- 2020-09-23 TW TW109132976A patent/TW202126685A/en unknown
- 2020-09-24 BR BR112022005024A patent/BR112022005024A2/en unknown
- 2020-09-24 CN CN202080066882.5A patent/CN114423788A/en active Pending
- 2020-09-24 CR CR20220122A patent/CR20220122A/en unknown
- 2020-09-24 PE PE2022000452A patent/PE20221315A1/en unknown
- 2020-09-24 KR KR1020227013747A patent/KR20220069076A/en unknown
- 2020-09-24 JO JOP/2022/0074A patent/JOP20220074A1/en unknown
- 2020-09-24 JP JP2022518746A patent/JP2022549005A/en active Pending
- 2020-09-24 WO PCT/EP2020/076685 patent/WO2021058636A1/en active Application Filing
- 2020-09-24 CA CA3154654A patent/CA3154654A1/en active Pending
- 2020-09-24 MX MX2022003544A patent/MX2022003544A/en unknown
- 2020-09-24 US US17/030,421 patent/US11661458B2/en active Active
- 2020-09-24 AU AU2020355599A patent/AU2020355599A1/en active Pending
- 2020-09-24 EP EP20781286.8A patent/EP4034161A1/en active Pending
-
2022
- 2022-03-20 IL IL291522A patent/IL291522A/en unknown
- 2022-03-23 CO CONC2022/0003324A patent/CO2022003324A2/en unknown
-
2023
- 2023-04-07 US US18/297,154 patent/US20230416378A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021058636A1 (en) | 2021-04-01 |
MX2022003544A (en) | 2022-04-11 |
JOP20220074A1 (en) | 2023-01-30 |
CR20220122A (en) | 2022-05-05 |
EP4034161A1 (en) | 2022-08-03 |
CA3154654A1 (en) | 2021-04-01 |
US20230416378A1 (en) | 2023-12-28 |
AU2020355599A1 (en) | 2022-04-07 |
JP2022549005A (en) | 2022-11-22 |
CO2022003324A2 (en) | 2022-04-19 |
US20210087282A1 (en) | 2021-03-25 |
PE20221315A1 (en) | 2022-09-07 |
CN114423788A (en) | 2022-04-29 |
KR20220069076A (en) | 2022-05-26 |
US11661458B2 (en) | 2023-05-30 |
IL291522A (en) | 2022-05-01 |
TW202126685A (en) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021019854A2 (en) | Anti-sema3a antibodies and their uses for the treatment of eyes or eye diseases | |
BR112017027778A2 (en) | factor xi antibodies and methods of use | |
BR112019018863A8 (en) | MAGE-A1 SPECIFIC HIGH AFFINITY TCRS AND USES THEREOF | |
BR112021016620A2 (en) | Azepino-Indoles and Other Heterocycles for the Treatment of Brain Disorders | |
BR112016025009A2 (en) | Human Antibodies to Middle East Respiratory Syndrome - Surface Protein | |
BR112018017172A2 (en) | anti-alpha-synuclein monoclonal antibodies for prevention of tau aggregation | |
BR112017005517A2 (en) | antiage antibodies for the treatment of inflammation and autoimmune disorders | |
BR112019005139A2 (en) | anti-il-33 antibodies and uses thereof | |
BR112022016382A2 (en) | SPECIFIC TRIPTAMINES FOR USE IN THE TREATMENT OF MOOD DISEASES | |
BR112018067721A2 (en) | hyperphosphorylated tau specific antibodies for the treatment of eye diseases | |
BR112018070357A2 (en) | anti-complement antibodies against factor bb and their uses | |
EA202191764A1 (en) | SUBSTITUTED OXOPYRIDINE DERIVATIVES | |
BR112017013696A2 (en) | peptides and their use in skin treatment | |
BR112022014949A2 (en) | COMPOUNDS AND USES THEREOF | |
BR112022015110A2 (en) | COMPOUNDS AND USES THEREOF | |
WO2020021480A3 (en) | Compositions and methods for treating the eye | |
BR112018012927A2 (en) | cftr regulators and methods of use | |
BR112022007595A2 (en) | METHODS TO TREAT ALZHEIMER'S DISEASE | |
BR112022002579A2 (en) | Antibodies against ilt2 and their use | |
BR112019022912A2 (en) | METHODS AND COMPOSITIONS TO TREAT ALLERGIC EYE DISEASES | |
BR112017020610A2 (en) | ANTI-DKK-1- ANTI-RANKL BIESPECIFIC ANTIBODY COMPOUNDS | |
BR112021020116A2 (en) | Anti-integrin antibodies and their uses | |
BR112018012949A2 (en) | cftr regulators and methods of use | |
BR102020023578A8 (en) | COMPOSITIONS AND METHODS FOR EYE TREATMENT | |
BR112022015109A2 (en) | COMPOUNDS AND USES THEREOF |